Open an account

MannKind

MNKD · NASDAQ

$3.10+$0.01 (+0.32%)TodayMarket closed ·
Prev close $3.09

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 592 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Employees
592
Headquarters
Danbury, Connecticut
Listed
Jul 28, 2004
Sector
Health Care
Industry
Biotechnology
Website
mannkindcorp.com

MNKD key statistics

Market cap
993.57M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.69M
Volume
1.90M
Open price
$3.11
High today
$3.18
Low today
$3.08
52 Week high
$6.51
52 Week low
$2.23

MannKind (MNKD) at a glance

As of Oct 20, 2026, MannKind (MNKD) shares are priced at $3.10, giving the company a market cap of 993.57M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.08 and $3.18. The current price is 0.6% above the day's low and 2.5% below its high.

Volume so far is 1.90M shares, below the average of 5.69M shares a day.

Over the past year MannKind has ranged from $2.23 to $6.51, and now sits 20% of the way up that range.

MannKind met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.06 per share against an estimate of -$0.0015.

The average analyst price target is $8.13, 162.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 10 analystsAvg $8.13
Low
$4.80
Now
$3.10
High
$13.65

MNKD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 205.9% on average.

  1. Q3 FY24: reported $0.02 per share against an estimate of $0.0306
  2. Q4 FY24: reported $0.03 per share against an estimate of $0.0367
  3. Q1 FY25: reported $0.04 per share against an estimate of $0.0449
  4. Q2 FY25: reported $0.00 per share against an estimate of $0.0481
  5. Q3 FY25: reported $0.067 per share against an estimate of $0.0219
  6. Q4 FY25: reported -$0.05 per share against an estimate of $0.0147
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0015
  8. Q2 FY26: reported -$0.06 per share against an estimate of -$0.0015

MNKD news

  • Vandana Singh

    Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

  • Vandana Singh

    FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

  • Press releasePRNewswire

    The $59B Quiet Shift Reshaping How Patients Access Care

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releasePRNewswire

    A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Similar companies

Companies in the same industry as MannKind

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.